Literature DB >> 2931381

Ciprofloxacin-induced hematuria.

F Garlando, M G Täuber, B Joos, O Oelz, R Lüthy.   

Abstract

We used ciprofloxacin, a quinolone-derivative, to treat a lung infection due to Pseudomonas aeruginosa in an adult cystic fibrosis patient. On three different occasions the use of ciprofloxacin was associated with the development of an asymptomatic hematuria with red blood cell casts. The mechanism responsible for this hematuria is presently unknown, but clinicians should be aware of this potential adverse effect of ciprofloxacin.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2931381     DOI: 10.1007/BF01642807

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  4 in total

Review 1.  The nephrotoxicity of antimicrobial agents (third of three parts).

Authors:  G B Appel; H C Neu
Journal:  N Engl J Med       Date:  1977-04-07       Impact factor: 91.245

2.  Dose- and sex-independent disposition of ciprofloxacin.

Authors:  D Höffler; A Dalhoff; W Gau; D Beermann; A Michl
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

3.  Comparative activities of ciprofloxacin (Bay o 9867), norfloxacin, pipemidic acid, and nalidixic acid.

Authors:  H L Muytjens; J van der Ros-van de Repe; G van Veldhuizen
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

4.  Comparison of high-pressure liquid chromatography and bioassay for determination of ciprofloxacin in serum and urine.

Authors:  B Joos; B Ledergerber; M Flepp; J D Bettex; R Lüthy; W Siegenthaler
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

  4 in total
  10 in total

Review 1.  Quinolone antimicrobial agents: adverse effects and bacterial resistance.

Authors:  J S Wolfson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

Review 2.  Tolerability of fluoroquinolone antibiotics. Past, present and future.

Authors:  P Ball; G Tillotson
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

3.  Investigation on renal tolerability of ciprofloxacin with tests based on monoclonal antibodies.

Authors:  F W Falkenberg; A W Mondorf
Journal:  Infection       Date:  1988       Impact factor: 3.553

Review 4.  Clinical features and management of adverse effects of quinolone antibacterials.

Authors:  J H Paton; D S Reeves
Journal:  Drug Saf       Date:  1991 Jan-Feb       Impact factor: 5.606

Review 5.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

6.  Ciprofloxacin in typhoid fever.

Authors:  A Bavdekar; M Chaudhari; S Bhave; A Pandit
Journal:  Indian J Pediatr       Date:  1991 May-Jun       Impact factor: 1.967

Review 7.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

8.  Randomized trial comparing ciprofloxacin plus netilmicin versus piperacillin plus netilmicin for empiric treatment of fever in neutropenic patients.

Authors:  C C Chan; B A Oppenheim; H Anderson; R Swindell; J H Scarffe
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

9.  Detection of Ciprofloxacin in Urine through Sensitized Lanthanide Luminescence.

Authors:  Subhankar Singha; Kyo Han Ahn
Journal:  Sensors (Basel)       Date:  2016-12-05       Impact factor: 3.576

10.  Adverse reactions to fluoroquinolones in the Nigerian population: an audit of reports submitted to the National Pharmacovigilance Centre from 2004 to 2016.

Authors:  Ibrahim A Oreagba; Kazeem A Oshikoya; Comfort Ogar; Abiodun O Adefurin; Ali Ibrahim; Olufunsho Awodele; Yetunde Oni
Journal:  Pharmacol Res Perspect       Date:  2017-02-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.